Monitor for the actual sale on Form 4 to confirm execution. The $2.7M sale is modest relative to the $2.2B market cap and follows recent insider selling patterns. No immediate price catalyst, treat as routine portfolio diversification by an officer.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 29 $26.88entry
- T+1 · 5mo ago +0.37%α −0.41% · $26.98
- T+5 · 4mo ago +8.33%α +6.95% · $29.12
- T+20 · 4mo ago −0.63%α −0.35% · $26.71
- T+60 · 8w ago +9.38%α +4.99% · $29.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Eric Warren, an officer of Mineralys Therapeutics, filed a Form 144 notice of intent to sell 104,124 shares of common stock, with an approximate market value of $2.7 million based on the filing date. The shares were acquired via a cashless exercise of employee stock options on June 26, 2026. This is a routine insider sale by an officer, not a transformative event, and the filing signals intent to sell, not a completed transaction.
Key Facts
- Filer: Eric Warren, an officer of Mineralys Therapeutics
- Shares to be sold: 104,124 shares of common stock
- Approximate market value: $2,696,321.98 (based on filing date price of ~$25.90/share)
- Acquisition: Shares acquired via cashless exercise of employee stock options on June 26, 2026
- Broker: Merrill Lynch, 225 Liberty Street, New York, NY
- Filing date: June 29, 2026; proposed sale date: June 26, 2026
- Exchange: NASDAQ
- Recent insider activity (30d): 3 sells totaling $425K prior to this filing
Financial Impact
Proposed sale of 104,124 shares valued at approximately $2.7 million, representing about 0.12% of the company's $2.2B market cap
Risk Factors
- Insider selling ahead of potential negative catalysts (e.g., clinical trial readouts, regulatory decisions) could signal lack of confidence
- Accumulation of insider sales over time may weigh on sentiment if not offset by insider buying
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001964306-26-000299 |
| Document: 0001964306-26-000299-index.html | 0001964306-26-000299 |
| Document: 0001964306-26-000299.txt | 0001964306-26-000299 |
Track record
35 reports on MLYS
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.97% at T+20 after the Jun 11, 2026 report. 5 of 10 went positive at some point.
Filters
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $15.81 Now $14.53 −8.10% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $15.24 Now $14.53 −4.66% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $15.99 Now $14.53 −9.13% settles Dec 2
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $18.18 Now $14.53 −20.08% settles Nov 30
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $21.38 Now $14.53 −32.04% settles Nov 25
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 19, 202628d ago 8-K Neutral 2/10 Entry $21.58 Now $14.53 −32.67% settles Nov 17
- Oct 13, 20264w ago 144 Neutral 3/10 Entry $20.76 to $16.16 Now $14.53 −30.01% ▼ −22.16% −20.89% vs SPY
- Sep 30, 20266w ago 144 Neutral 3/10 Entry $23.72 to $21.24 Now $14.53 −38.74% ▼ −10.46% −11.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers